Cross-source identity
National Provider Identifier 1215933379 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1215933379 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1215933379 | 821 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1215933379 | 77 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity fcb86277… | Canonical resolved node · 4 identifier(s) · 9 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $380,900 | 112 |
| Consulting Fee | $271,070 | 68 |
| Travel and Lodging | $89,853 | 288 |
| Honoraria | $49,642 | 15 |
| Compensation for serving as faculty or as a speaker for a medical education program |
| Manufacturer | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $175,349 | 164 |
| Abbvie Inc. | $127,100 | 92 |
| Otsuka America Pharmaceutical, Inc. | $106,862 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Ingrezza(Valbenazine Tosylate) | 13 | $108,866 |
| Ativan(Lorazepam) | 11 | $95,226 |
| Aristada(Aripiprazole Lauroxil) | 25 | $74,740 |
| Vraylar(Cariprazine Hcl) | 37 | $41,625 |
| Caplyta(Lumateperone Tosylate) | 20 | $40,492 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Pharmaceuticals, Inc (NJ) | cms_open_payments |
| ← pays | Janssen Scientific Affairs, Llc (NJ) | cms_open_payments |
| ← pays | Neos Therapeutics, Lp (CO) | cms_open_payments |
| ← pays | Noven Pharmaceuticals, Inc. (FL) | cms_open_payments |
| ← pays | Noven Therapeutics, Llc (FL) | cms_open_payments |
| ← pays | Corium, Llc (MA) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Biogen, Inc. (MA) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| $20,860 |
| 12 |
| 133 |
| Neurocrine Biosciences, Inc. | $77,511 | 68 |
| Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) | $61,447 | 69 |